Donate

Phase III Trial Comparing Orteronel (TAK-700) Plus Prednisone Against Placebo Plus Prednisone Fails

Reporting both negative clinical trial results is as important as reporting positive results. However, pharmaceutical companies often bury negative results. Fortunately (actually unfortunately because there were negative results) a Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed [...]

Cabozantinib Fails In the Phase III COMET-1 Trial

The pharmaceutical company Exelixis has announced that their experimental treatment, cabozantinib has failed the Phase III clinical trial for men with metastatic castration-resistant prostate cancer (mCRPC). In the trial the experimental treatment cabozantinib was compared to the drug prednisone. In the trial known as COMET-1, Cabozantinib, a tyrosine kinase inhibitor, did not meet its primary [...]

Go to Top